David A. Siegel Trevena Inc Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.2 - $0.5 $40,540 - $101,350
-202,700 Reduced 91.02%
20,000 $8,000
Q1 2022

May 16, 2022
SELL
$0.41 - $0.63 $74,619 - $114,658
-181,998 Reduced 44.97%
222,700 $122,000
Q4 2021

Feb 14, 2022
BUY
$0.57 - $1.29 $202,747 - $458,850
355,698 Added 725.91%
404,698 $236,000
Q3 2021

Nov 15, 2021
BUY
$1.11 - $1.7 $54,390 - $83,300
49,000 New
49,000 $60,000
Q2 2021

Aug 16, 2021
SELL
$1.46 - $2.25 $1.19 Million - $1.83 Million
-814,300 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$1.77 - $2.93 $1.34 Million - $2.22 Million
757,000 Added 1321.12%
814,300 $1.46 Million
Q4 2020

Feb 16, 2021
BUY
$2.13 - $3.26 $122,049 - $186,798
57,300 New
57,300 $123,000
Q3 2020

Nov 16, 2020
SELL
$1.53 - $3.13 $22,491 - $46,011
-14,700 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$0.48 - $1.75 $7,056 - $25,725
14,700 New
14,700 $22,000
Q1 2020

May 15, 2020
SELL
$0.56 - $0.97 $12,656 - $21,922
-22,600 Closed
0 $0
Q4 2019

Feb 14, 2020
BUY
$0.62 - $1.06 $2,054 - $3,511
3,313 Added 17.18%
22,600 $19,000
Q3 2019

Nov 14, 2019
SELL
$0.81 - $1.06 $2,926 - $3,829
-3,613 Reduced 15.78%
19,287 $19,000
Q2 2019

Aug 14, 2019
SELL
$0.94 - $1.6 $20,022 - $34,080
-21,300 Reduced 48.19%
22,900 $24,000
Q1 2019

May 15, 2019
SELL
$0.51 - $1.88 $9,537 - $35,156
-18,700 Reduced 29.73%
44,200 $69,000
Q4 2018

Feb 14, 2019
BUY
$0.39 - $3.47 $6,396 - $56,908
16,400 Added 35.27%
62,900 $27,000
Q3 2018

Nov 14, 2018
BUY
$1.39 - $2.25 $24,742 - $40,050
17,800 Added 62.02%
46,500 $99,000
Q2 2018

Aug 14, 2018
BUY
$1.44 - $2.24 $41,328 - $64,288
28,700 New
28,700 $41,000

About TREVENA INC

TRVN Quotes by TradingView
  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email